TAK-981   Click here for help

GtoPdb Ligand ID: 11305

Synonyms: Example 133 [WO2016004136A1] | I-263a [WO2016004136A1] | subasumstat (proposed INN) | TAK981
Immunopharmacology Ligand
Compound class: Synthetic organic
Comment: TAK-981 is an inhibitor of the protein post-translational modification, SUMOylation. SUMO is a small ubiquitin-like modifier that is attached to proteins by enzymes of the SUMOylation complex (sumo activating enzyme, SAE) [2], and its attachment regulates protein function. SUMOylation has emerged as an important pathway in oncogenic processes, making SAE an oncology drug target. TAK-981 inhibits SUMOylation and has been shown to induce anti-tumour immunity in preclinical models. The precise molecular target for TAK-981 has not been disclosed.
The chemical structure that was submitted to the WHO for the INN subasumstat is identical to the chemical structure of TAK-981 that is held by PubChem, and is claimed in patent WO2016004136A1 by a team from Millennium Pharmaceuticals.
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 10
Hydrogen bond donors 4
Rotatable bonds 8
Topological polar surface area 193.15
Molecular weight 577.12
XLogP 0.9
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES Clc1ccc2c(c1)[C@@H](NCC2)c1cc(sc1C)C(=O)c1cncnc1N[C@@H]1C[C@@H]([C@H](C1)O)COS(=O)(=O)N
Isomeric SMILES Clc1ccc2c(c1)[C@@H](NCC2)c1cc(sc1C)C(=O)c1cncnc1N[C@@H]1C[C@@H]([C@H](C1)O)COS(=O)(=O)N
InChI InChI=1S/C25H28ClN5O5S2/c1-13-18(23-19-7-16(26)3-2-14(19)4-5-29-23)9-22(37-13)24(33)20-10-28-12-30-25(20)31-17-6-15(21(32)8-17)11-36-38(27,34)35/h2-3,7,9-10,12,15,17,21,23,29,32H,4-6,8,11H2,1H3,(H2,27,34,35)(H,28,30,31)/t15-,17-,21+,23+/m1/s1
No information available.
Summary of Clinical Use Click here for help
TAK-981 has advanced to clinical evaluation in solid tumours and hematological malignancies.COVID-19: As an extension arm of NCT03648372, TAK-981 will be tested in a subgroup of cancer study patients with COVID-19. Enrollment into this COVID arm ended at the beginning of October 2020.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT04065555 Intratumoral Microdosing of TAK-981 in Head and Neck Cancer Early Phase 1 Interventional Presage Biosciences
NCT03648372 A Study to Evaluate the Safety, Tolerability and Pharmacokinetics (PK) of TAK-981 in Adult Participants With Advanced or Metastatic Solid Tumors or Relapsed/Refractory Hematologic Malignancies and in a Subset With Coronavirus Disease 2019 (COVID-19) Phase 1 Interventional Takeda
NCT04074330 A Study of TAK-981 in Combination With Rituximab in Participants With Relapsed/Refractory (r/r) CD20-positive (CD20+) Non-Hodgkin Lymphoma (NHL) Phase 1/Phase 2 Interventional Takeda
NCT04381650 A Safety and Efficacy Study of TAK-981 Plus Pembrolizumab in Participants With Select Advanced or Metastatic Solid Tumors Phase 1/Phase 2 Interventional Takeda